{"disease":{"id":"epilepsy-intractable","name":"epilepsy intractable"},"drugs":{"marketed":[{"drug_id":"keppra","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"topiramate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topamax","generic_name":"topiramate","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tiagabine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gabitril","generic_name":"TIAGABINE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Sodium- and chloride-dependent GABA transporter 1","drug_class":"Anti-epileptic Agent","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"phenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"carbamazepine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"levetiracetam","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"carbamazepin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"phenobarbitone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fosphenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"mephenytoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesantoin","generic_name":"MEPHENYTOIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"primidone","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethotoin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Peganone","generic_name":"ETHOTOIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"Sodium channel alpha subunit","drug_class":"Anti-epileptic Agent","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dilantin","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"topamax","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Topamax","company_name":"Ataturk University","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phenacemide","indication_name":"Epilepsy characterized by intractable complex partial seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenurone","generic_name":"PHENACEMIDE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"Sodium channel protein type 1 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04286776","title":"Memory Retrieval and Encoding Investigated by Neural Stimulation","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05332990","title":"Multicenter Comparison of Interictal HFO as a Predictor of Seizure Freedom","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04649008","title":"Localizing Epileptic Networks Using MRI and iEEG","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04500119","title":"Neuronal Mechanisms of Human Episodic Memory","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT05248269","title":"Thermocoagulation in Drug Resistant Focal Epilepsy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","has_results":false},{"nct_id":"NCT06581133","title":"Sleep Disruption Pattern - Epilepsy Monitoring Unit","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05406349","title":"Neural Mechanisms of Spatial Representations Beyond the Self","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Boston University Charles River Campus","has_results":false},{"nct_id":"NCT06310954","title":"Ketogenic Diet in Pediatric Intractable Epilepsy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":59,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05503511","title":"Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"NeuroPro Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06489561","title":"Neural Computations of Goal-directed Decision-making","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT03702127","title":"TMS - Intracranial Electrodes","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Aaron Boes","has_results":false},{"nct_id":"NCT03403907","title":"The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"María Gómez Eguílaz","has_results":false},{"nct_id":"NCT06602570","title":"The Mosaic Brain: a New Diagnostic Approach in Focal Epilepsies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Institute of Child Health","has_results":false},{"nct_id":"NCT06545643","title":"Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04325360","title":"Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"University of Campinas, Brazil","has_results":false},{"nct_id":"NCT04399954","title":"Evaluation of Ketoflo","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Vitaflo International, Ltd","has_results":false},{"nct_id":"NCT05339126","title":"RNS System LGS Feasibility Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"NeuroPace","has_results":false},{"nct_id":"NCT04763070","title":"Ciprofloxacin in Drug-resistant Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Mazandaran University of Medical Sciences","has_results":false},{"nct_id":"NCT02987114","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"PhytoTech Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT03857074","title":"Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT03646240","title":"ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT03886753","title":"Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT03790436","title":"Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet","phase":"NA","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT04158531","title":"REC2Stim as a Treatment for Refractory Epilepsy in the Primary Sensorimotor Cortex.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05727943","title":"Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT07222878","title":"Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"NeuroPro Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03955432","title":"Long-term Cardiac Monitoring in Epilepsy","phase":"NA","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT03860298","title":"Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"NaviFUS Corporation","has_results":false},{"nct_id":"NCT05015868","title":"Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies","phase":"NA","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"IRCCS Eugenio Medea","has_results":false},{"nct_id":"NCT05437393","title":"Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University College, London","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}